Xcout IntelEliksa Therapeutics competitors & alternatives
The 12 closest competitors and alternatives to Eliksa Therapeutics among biotechnology companies — ranked by similarity to what Eliksa Therapeutics actually does, not by market-cap band.
Subscribe to see Eliksa Therapeutics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Eliksa Therapeutics
Eliksa Therapeutics, Inc. is a venture-backed biotechnology company based in Doylestown, Pennsylvania, specializing in regenerative medicine. The company focuses on developing innovative therapies to treat severe conditions such as Epidermolysis bullosa (EB). Through targeted research and funding, it works to advance clinical solutions for patients with rare genetic skin diseases.
Eliksa Therapeutics at a glance
Eliksa Therapeutics is a biotechnology company headquartered in United States. Its most recent funding round, Seed, closed in October 2025. Xcout tracks 1 named person at Eliksa Therapeutics, including Armen Karamanian (Chief Executive Officer).
Eliksa Therapeutics leadership
- Armen KaramanianChief Executive Officer
Eliksa Therapeutics funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Seed | Undisclosed | 5 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Eliksa Therapeutics competitors
Ranked by semantic similarity — how close each company is to Eliksa Therapeutics by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
ReadOn Therapeutics is a non-profit biotechnology organization focused on developing novel readthrough therapeutics for Epidermolysis Bullosa (EB). Operating with a presence in locations such as Munich, Germany, the organization partners with research entities like DEBRA Research to accelerate treatments for rare genetic disorders. Its scientific focus lies in advancing translational research to meet significant unmet medical needs.
Similar biotechnology company
Rinascera Therapeutics, Inc. is a clinical-stage biotechnology company located in Boston, Massachusetts, dedicated to transforming the treatment of rare genetic skin diseases.
Similar biotechnology company
Nova Anchora is a San Francisco-based biopharmaceutical company founded in 2021 that develops advanced topical protein therapies for rare skin diseases. The company's lead product in development, NvA-011, is a recombinant version of collagen VII designed as a topical gel for the treatment of dystrophic epidermolysis bullosa.
Similar biotechnology company
Kamal Therapeutics, Inc. is a pharmaceutical holding company located in Hingham, Massachusetts, focused on developing treatments such as intravenous recombinant human decorin for dystrophic epidermolysis bullosa.
Biotech
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.
Similar biotechnology company
Palvella Therapeutics is a biotechnology company headquartered in Wayne, Pennsylvania, that specializes in developing and commercializing medicines for patients with rare dermatological diseases. The publicly traded company operates with corporate offices and an active team dedicated to clinical and commercial development.
Similar biotechnology company
Mariposa Therapeutics Ltd is a biotechnology company founded in 2019 and headquartered in Cardiff, United Kingdom. The company is dedicated to researching and developing innovative therapeutic solutions for keratin-related disorders. Its scientific efforts are supported by specialized research investments aimed at addressing rare skin and tissue conditions.
Biotech
Abeona Therapeutics Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of gene and cell therapies to combat critical, uncommon genetic illnesses. Their foremost developmental asset is EB-101, a personalized gene-corrected cell therapy that has progressed to Phase III clinical trials for the treatment of recessive dystrophic epidermolysis bullosa. The company's pipeline also encompasses several other programs: ABO-102, an adeno-associated virus (AAV)-based gene therapy designed for Sanfilippo syndrome type A; ABO-201, aimed at CLN3 disease; ABO-401, targeting cystic fibrosis; and ABO-50X, intended for genetic eye disorders. Additionally, Abeona actively advances AAV-based gene therapies through its proprietary AIM vector platform. Incorporated in 1974, the firm was initially named PlasmaTech Biopharmaceuticals, Inc. before officially adopting the name Abeona Therapeutics Inc. in June 2015. The company's corporate base is situated in New York, New York.
Similar biotechnology company
Eluciderm Inc. is a clinical-stage regenerative medicine small-molecule pharmaceutical company that uses a selective multi-PARP modulation platform to alter the body’s response to inflammation and injury. The company develops therapeutics designed to enable organized tissue regeneration, enhance wound healing, and minimize scarring following trauma.
Similar biotechnology company
Aldena Therapeutics is a biotechnology company focused on transforming dermatology through novel siRNA-based treatments for skin conditions.
Biotech
Azitra, Inc. is a pre-clinical biopharmaceutical company focused on developing precise treatments for various dermatological conditions. They innovate by utilizing engineered proteins and live biotherapeutic products to address skin diseases. The company's pipeline features several key therapeutic candidates: ATR-12: A genetically modified strain of S. epidermidis intended to treat Netherton syndrome, a specific skin disorder. ATR-04: Another modified S. epidermidis strain, designed to alleviate the papulopustular rash commonly experienced by cancer patients undergoing epidermal growth factor receptor inhibitor therapy. ATR-01: An engineered recombinant human filaggrin protein developed for the treatment of ichthyosis vulgaris, another dermatological ailment. Founded in 2014, Azitra, Inc. operates from its headquarters in Branford, Connecticut.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Eliksa Therapeutics and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Eliksa Therapeuticsand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →